BLCO (Bausch & Lomb) Beneish M-Score: -2.59 (As of Jun. 26, 2026)

What is Bausch & Lomb Beneish M-Score?

Bausch & Lomb BLCO +2.58% 77 Beneish M-Score is -2.59 as of Jun. 26, 2026. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.29 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Bausch & Lomb ranks better than 51.04% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.59 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Bausch & Lomb's Beneish M-Score or its related term are showing as below:

BLCO' s Beneish M-Score Range Over the Past 10 Years
Min: -3.31 Med: -2.53 Max: -2.4
Current: -2.59

During the past 8 years, the highest Beneish M-Score of Bausch & Lomb was -2.40. The lowest was -3.31. And the median was -2.53.

Bausch & Lomb Beneish M-Score Related Terms

Bausch & Lomb Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Bausch & Lomb's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch & Lomb Beneish M-Score Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beneish M-Score

Get a 7-Day Free Trial

0.00

-3.31

-2.54

-2.43

-2.53

Bausch & Lomb Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Beneish M-Score	Get a 7-Day Free Trial															-2.50	-2.52	-2.46	-2.53	-2.59

BLCO vs ISRG, BDX, MDLN: Beneish M-Score Comparison

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch & Lomb Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's Beneish M-Score falls into.

Save Embed

77GF Score

Bausch & Lomb Corp BLCO

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Bausch & Lomb Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bausch & Lomb for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1.0184

0.528 * 0.9903

0.404 * 0.9805

0.892 * 1.0785

0.115 * 1.1401

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.9593

4.679 * -0.033454

0.327 * 1.0247

-2.55

This Year (Mar26) TTM:

Last Year (Mar25) TTM:

Total Receivables was $1,106 Mil.
Revenue was 1244 + 1405 + 1281 + 1278 = $5,208 Mil.
Gross Profit was 761 + 872 + 771 + 753 = $3,157 Mil.
Total Current Assets was $2,776 Mil.
Total Assets was $13,780 Mil.
Property, Plant and Equipment(Net PPE) was $1,794 Mil.
Depreciation, Depletion and Amortization(DDA) was $416 Mil.
Selling, General, & Admin. Expense(SGA) was $2,215 Mil.
Total Current Liabilities was $1,820 Mil.
Long-Term Debt & Capital Lease Obligation was $5,031 Mil.
Net Income was -71 + -58 + -28 + -62 = $-219 Mil.
Non Operating Income was -30 + -50 + 15 + -33 = $-98 Mil.
Cash Flow from Operations was 32 + 136 + 137 + 35 = $340 Mil.

Total Receivables was $1,007 Mil.
Revenue was 1137 + 1280 + 1196 + 1216 = $4,829 Mil.
Gross Profit was 655 + 779 + 732 + 733 = $2,899 Mil.
Total Current Assets was $2,694 Mil.
Total Assets was $13,428 Mil.
Property, Plant and Equipment(Net PPE) was $1,581 Mil.
Depreciation, Depletion and Amortization(DDA) was $432 Mil.
Selling, General, & Admin. Expense(SGA) was $2,141 Mil.
Total Current Liabilities was $1,726 Mil.
Long-Term Debt & Capital Lease Obligation was $4,789 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(1106 / 5208)	/	(1007 / 4829)
	=	0.212366	/	0.208532
	=	1.0184

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(2899 / 4829)	/	(3157 / 5208)
	=	0.600331	/	0.606183
	=	0.9903

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (2776 + 1794) / 13780)	/	(1 - (2694 + 1581) / 13428)
	=	0.66836	/	0.681635
	=	0.9805

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	5208	/	4829
	=	1.0785

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(432 / (432 + 1581))	/	(416 / (416 + 1794))
	=	0.214605	/	0.188235
	=	1.1401

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(2215 / 5208)	/	(2141 / 4829)
	=	0.425307	/	0.443363
	=	0.9593

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((5031 + 1820) / 13780)	/	((4789 + 1726) / 13428)
	=	0.49717	/	0.48518
	=	1.0247

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-219 - -98	-	340)	/	13780
	=	-0.033454

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Bausch & Lomb has a M-score of -2.55 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of -2.59 mean?

Bausch & Lomb (BLCO) has a Beneish M-Score of -2.59 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bausch & Lomb and its competitors. According to the industry distribution chart, Bausch & Lomb ranks #375 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 49%.

Is Bausch & Lomb's Beneish M-Score too high?

Bausch & Lomb's current Beneish M-Score is -2.59. Based on the distribution chart, Bausch & Lomb ranks #375 out of 766 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Bausch & Lomb's Beneish M-Score compare to ISRG and BDX?

According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #375 out of 766 companies for Beneish M-Score. This puts Bausch & Lomb in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Medical Devices & Instruments company?

A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bausch & Lomb and its competitors. Bausch & Lomb's current Beneish M-Score is -2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Bausch & Lomb stock overvalued right now?

Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.29, compared to a current price of $15.91 — trading 13% below its estimated fair value. The current Beneish M-Score is -2.59. Bausch & Lomb's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current Beneish M-Score is -2.59 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch & Lomb (BLCO) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued. The current stock price of $15.91 is trading 13% below its estimated GF Value™ of $18.29. GuruFocus considers Bausch & Lomb to be Modestly Undervalued.

Key valuation signals for BLCO:

Beneish M-Score: -2.59
GF Value™: $18.29 vs. price of $15.91 (13% below fair value)
GF Score™: 77/100 with 10 warning signs

No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch & Lomb Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TSXV:ZEN TSXV:OTC TSXV:COV XCNQ:EYE XCNQ:DTR ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM XSWX:STMN XTER:SRT OCSE:COLO B NZSE:FPH SOLV

Other Exchanges S2L:Germany BLCO:Canada

Address 520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

77GF Score

Get the complete analysis for BLCO

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.91

Price

$18.29

GF Value

View BLCO Analysis

See Beneish M-Score data for all stocks →